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Introduction
CD1d belongs to the CD1 family of proteins that share
structural and functional homology to the MHC class I
and class II molecules (1, 2). CD1d is expressed by a
majority of thymocytes, resting B cells, DCs, and mono-
cytes (1, 3). In addition, CD1d expression is observed in
a variety of epithelial cell types, including hepatocytes
and intestinal epithelial cells (IECs) (4, 5). Although its
role has not been clearly defined in epithelia, CD1d is
known to associate with glycolipid antigens and present
them to subsets of CD1d-restricted T cells bearing NK
cell markers (NK-T cells) (2). Activation of CD1d-
restricted cells in vivo by association of CD1d with a
model lipid antigen, α-galactosylceramide, regulates
colitis in a chemically induced disease model (6, 7). In
these studies on colitis, α-galactosylceramide was
observed to localize to the surface of the intestinal
epithelium, raising the possibility that CD1d was func-
tional in this site in vivo. Moreover, intestinal epithelial
CD1d can signal the production of IL-10, which,
through autocrine pathways, can protect epithelia from
the deleterious influence of cytokines such as IFN-γ (8).
Such data have implicated CD1d as a molecule capable
of facilitating mechanisms that regulate mucosal
inflammation and highlight the CD1d-bearing IEC as
a candidate cell type in this immune regulation.
Immunostaining and biochemical analysis of tissues
from the human small and large intestine have revealed
the presence of CD1d on both the apical and the baso-
lateral membranes of IECs (9). In addition, CD1d is
observed intracellularly within subapical regions in these
cells. Relative to the levels of CD1d observed in freshly
isolated tissues, epithelium-derived cell lines, such as
T84 cells, express low levels of CD1d. The reasons for
such differences remain unclear. In these studies, we
hypothesized that extracellular components derived
from the intestinal milieu exist that are capable of influ-
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encing the levels of CD1d expressed by IECs. The lack of
such components under in vitro culture conditions
could explain, therefore, the relatively low level of CD1d
expression observed in model IEC lines. However, other
than the cytokine IFN-γ, essentially nothing is known
about what factors regulate CD1d expression on any cell
type (10). We now report that incubation of intestinal
epithelium–derived cell lines with soluble lumenal com-
ponents of the human and mouse gastrointestinal tract
results in upregulation of CD1d expression. Biochemi-
cal and functional characterization of this CD1d-induc-
ing activity from mouse and human samples identified
it to be soluble heat shock protein 110 (Hsp110). The
data presented from these studies predict a novel func-
tion for Hsp110, indicate the ability of lumenal compo-
nents to influence cell surface molecule expression on
IECs, and provide important insight into the mecha-
nisms of CD1d regulation in vivo and in vitro.
Methods
Antibodies. Two antibodies specific for human CD1d
were used in these studies. D5 is a mouse mAb of the
IgG2a isotype. This antibody was raised against a glu-
tathione-S-transferase-CD1d fusion protein contain-
ing the α1–α3 domains of CD1d (kindly provided by
Steven Balk, Beth Israel Deaconess Medical Center,
Boston, Massachusetts, USA; ref. 11). The mAb 51.1.3
(mouse IgG2b) was raised against an Fc-fusion protein
of CD1d (kindly provided by Steven Porcelli, Albert
Einstein Medical School, New York, New York, USA;
ref. 12). P2A4 is a mouse anti–human ICAM-1 mAb
and was obtained from the Developmental Studies
Hybridoma Bank (Iowa City, Iowa, USA). L243 is a
mouse mAb specific to human MHC class II (Ameri-
can Type Culture Collection, Rockville, Maryland,
USA). Polyclonal anti-Hsp110 antibodies were previ-
ously characterized (13).
In vitro cell culture. The colon-derived human epithe-
lial cell lines T84, HT-29, and Caco-2 were grown in a
1:1 mixture of Dulbecco/Vogt modified Eagle’s medi-
um and Ham’s F-12 medium, supplemented with 15
mM HEPES buffer (pH 7.5), 14 mM NaHCO3, 40
mg/ml penicillin, 8 mg/ml ampicillin, 90 mg/ml strep-
tomycin, and 6% FCS. Cultures were maintained at
37°C in a humidified incubator containing 5% CO2.
Cells were passaged every 7–14 days with 0.1% trypsin
and 0.9 mM EDTA in calcium- and magnesium-free
PBS. Where indicated, human microvascular endothe-
lial cells were used as described previously (14).
Exposure of epithelial cells to lumen-derived factors. Con-
fluent monolayers were incubated for varying periods
of time with preparations of lumen-derived samples
or indicated concentrations of purified recombinant
Hsp110 (15) on the apical and/or basolateral surface,
as indicated. Prior to their addition to cell cultures,
all samples were sterilized by passing of their con-
tents through a 0.22-µm sterile filter. The protein
concentration of each sample was also assessed by
use of the Bio-Rad protein assay reagent in accor-
dance with the manufacturer’s instructions (Bio-Rad
Laboratories Inc., Hercules, California, USA).
Preparative methods for purification and characterization of
lumenal contents. Six volunteers donated approximately
40 g of human feces each. Individual samples were
resuspended in 50 ml of PBS. Insoluble particulate
matter was sedimented by centrifugation at 13,000 g
for 10 minutes at room temperature and subsequently
discarded. Soluble components represented within the
supernatant were further clarified by passage through
a 0.22-µm sterile filter. The filtrate was defined as the
crude lumenal contents (LC) and was used as a starting
point from which to proceed with purification. In
order to remove LC factors of less than 10 kDa in
molecular weight, crude samples were dialyzed against
100 times their volume of PBS for a period of 4 hours
at 4°C. Molecules over 10 kDa were retained within the
confinement of the dialysis tube and were used in sub-
sequent stages of the fractionation procedure. Aqueous
and hydrophobic factors from LC samples were
resolved by chloroform-induced phase separation.
Briefly, 1 volume of chloroform was added to an equal
volume of LC material. The mixture was vortexed for
10 minutes, and phases were resolved by centrifugation
at 20,000 g for 20 minutes at room temperature. The
upper phase comprised those molecules that parti-
tioned to the aqueous solution and could be incubat-
ed with epithelial cells without the need for buffer
exchange. The lower phase, containing hydrophobic
factors, was dried and resuspended in PBS prior to sub-
sequent use. To fractionate LC material on the basis of
size, samples were passed under pressure through fil-
ters of varying molecular weights, ranging from 100
kDa to 10 kDa. Both filtrate and retentate from filtra-
tion procedures were applied to epithelial monolayers
to assess elevations in CD1d expression.
Peptide microsequencing. In subsets of experiments, par-
tially purified fractions of LC were resolved by SDS-
PAGE and stained by the Coomassie method, and the
resulting approximately 100-kDa band (∼100 pmol)
was extracted and submitted to the Dana-Farber Can-
cer Institute Peptide Core Facility (Boston, Massachu-
setts, USA) for trypsin digestion and microsequence
analysis, using previously described protocols (16).
Preparation of intestine-derived material from mice. Groups
of 6- to 12-week-old female mice of the BALB/c strain,
bred under either specific pathogen–free (SPF) or
germfree conditions, were used as previously described
(17). All mice were sacrificed by asphyxiation in a carbon
dioxide–saturated chamber followed by cervical dislo-
cation. Lumenal components were then isolated from
the stomach and the small and large intestine. Mucosal
scrapings, representing the mucin-rich epithelial
mucosa, were also isolated from the small and large
intestine. Both mucous material and lumenal material
were suspended in PBS (pH 7.4) and tested for their abil-
ity to upregulate CD1d on epithelial monolayers.
ELISA. Expression of epithelial cell surface proteins
was evaluated by use of a cell surface ELISA, as previ-
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ously described on 96-well plates (18) or on permeable
supports (19). The anti-CD1d antibody 51.1.3 was used
at a final concentration of 30 µg/ml in HBSS contain-
ing 0.5% BSA. Antibodies specific to ICAM-1 (P2A4)
and MHC class II (L243) were used as undiluted
hybridoma supernatants. All incubations were per-
formed at 4°C for a period of 2 hours. Control samples
were stained with isotype-matched antibodies and the
secondary peroxidase conjugate. Data are presented as
mean ODs at 405 nm blanked against values obtained
from isotype-matched control samples. Variations
between samples treated under one condition are rep-
resented by SEM.
Analysis of mRNA levels by RT-PCR. Epithelial cells were
lysed in Trizol reagent (GIBCO BRL; Life Technologies
Inc., Rockville, Maryland, USA), and total cell RNA was
purified according to the manufacturer’s instructions.
RNA samples were then treated with DNase I (Gen-
Hunter Corp., Nashville, Tennessee, USA) to remove any
contaminating DNA. Reverse transcription was per-
formed using a cDNA synthesis kit from BD Biosciences
Clontech (Palo Alto, California, USA). Briefly, 1 µg of
total RNA was added to a reaction mixture of 50 mM
Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 µM of
each dNTP, 20 pmol oligo-(dT)18 primer, 20 IU RNase
inhibitor, and 200 IU Moloney murine leukemia virus
reverse transcriptase in a final volume of 20 µl. Single-
stranded cDNA was synthesized using a Thermocycler
(model PTC-200; MJ Research Inc.) set to perform one
cycle at 42°C for 60 minutes followed by a second cycle
at 94°C for 5 minutes. Amplification of CD1d-encoding
transcripts by PCR was performed as described previ-
ously (10) using the Platinum Taq High Fidelity enzyme
mix containing 1 µM each of the CD1d-specific sense
primer (5′-TTATCGAAGCAGCTTCACCAGG-3′) and the
antisense primer (5′-GATACCATGTCTCGTCAGCATT-3′).
Amplification reactions consisted of a 2-minute denat-
uration step at 94°C and a 1-minute annealing step at
60°C, followed by repeated cycles of 68°C for 1 minute,
94°C for 45 seconds, and 60°C for 1 minute. At the end
of the reaction, a final extension step was performed at
72°C for 10 minutes. Two rounds of amplification were
required to detect CD1d-encoding transcripts, as previ-
ously described (10). The first round consisted of 25
cycles, and the second round consisted of 15 cycles. Prod-
ucts of PCR were resolved on a 1% agarose gel contain-
ing ethidium bromide. A 518-bp fragment correspon-
ding to CD1d transcript expression was visualized under
ultraviolet light. To ensure that equal quantities of tem-
plate had been loaded between samples, the housekeeping
gene GAPDH was amplified using 1 µM of the gene-spe-
cific primer pair purchased from CLONTECH Laborato-
ries Inc. GAPDH fragments appeared as a 983-bp band
when resolved by electrophoresis on a 1% agarose gel.
Immunoprecipitation and Western blot analysis. Following
experimental conditions, epithelial monolayers were
washed with ice-cold HBSS and lysed in 500 ml of RIPA
buffer consisting of 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
500 mM phenylmethanesulfonyl fluoride, and 1
mg/ml each of pepstatin, aprotinin, and leupeptin.
Insoluble material was removed by centrifugation at
13,000 g for 10 minutes at 4°C. Supernatants, normal-
ized for protein concentration, were precleared by rota-
tion with normal mouse serum and protein A–conju-
gated Sepharose beads. CD1d from cell lysates was
precipitated with 20 µg of either D5 or 51.1.3 bound to
protein A-Sepharose. Incubations with CD1d-specific
antibodies were performed overnight at 4°C. Immuno-
precipitates were washed with RIPA buffer, boiled in 1×
reducing Laemmli buffer, and resolved by 12% SDS-
PAGE. Proteins were transferred to nitrocellulose and
blocked overnight in PBS containing 5% nonfat dry
milk and 0.05% Tween-20. Nitrocellulose blots were
then incubated for 1 hour with D5 antibody (4 µg/ml)
followed by species-matched peroxidase-conjugated
IgG (1 µg/ml) for 45 minutes. In subsets of experi-
ments, Hsp110 in LC was determined by Western blot
using rabbit polyclonal antisera, as previously
described (13). HRP detection on nitrocellulose blots
was achieved using ECL.
Localization of Hsp110 in human tissue. Cryopreserved
human large and small intestinal tissue samples were
obtained from the tissue bank of the Brigham and
Women’s Hospital and Massachusetts General Hospi-
tal. Samples were frozen in OCT compound (Bayer,
Elkhart, Indiana, USA) and stored at –80°C until use.
Four-micrometer-thick frozen sections were air-dried
for 20 minutes and stained by the avidin-biotin complex
method as previously described (20). Briefly, the sec-
tions were fixed in acetone for 10 minutes, air-dried, and
incubated with purified rabbit anti–human Hsp110
polyclonal antibody at 1:100 dilution for 1 hour. As a
negative control, parallel sections were incubated with
2% rabbit serum. After incubation, specimens were
incubated for 30 minutes with 0.3% hydrogen peroxide
in PBS to block endogenous peroxidase activity.
Endogenous biotin was blocked by sequential incuba-
tions with avidin (Vector Laboratories Inc., Burlingame,
California, USA) and biotin (Sigma-Aldrich, St. Louis,
Missouri, USA). Specimens were then incubated with
biotinylated goat anti-rabbit Ig (Vector Laboratories
Inc.) at 1:200 dilution followed by avidin-biotin HRP
complex (DAKO Corp., Carpinteria, California, USA).
After washing, the specimens were developed in a solu-
tion of 3-amino-9-ethylcarbazole (Aldrich Chemical Co.,
Milwaukee, Wisconsin, USA). After developing, speci-
mens were counterstained with hematoxylin and
mounted with Glycergel (DAKO Corp.).
In subsets of experiments, Hsp110 was localized to the
surface of primary culture enterocytes. Briefly, entero-
cytes were isolated by a method described previously
(21). Surgical specimens were obtained from the oper-
ating room. Specimens were washed extensively with
PBS containing 1% penicillin/streptomycin and 1%
Fungizone (Flow Laboratories, McLean, Virginia, USA).
The mucosa was stripped from the submucosa, minced,
and placed in 1 mM dithiothreitol (Sigma-Aldrich) for
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5 minutes at room temperature to remove the mucus.
The pieces were then washed in PBS and incubated in
dispase (3 mg/ml in RPMI 1640 medium; Roche
Applied Science, Indianapolis, Indiana, USA) for 30
minutes in a 37°C shaking incubator. This was repeat-
ed four times. The tissue pieces were removed and the
cell suspension collected, pooled, and centrifuged on a
Percoll density gradient (Amersham Biosciences Corp.,
Piscataway, New Jersey, USA). Enterocytes located at the
0–30% interface were washed three times with PBS and
resuspended in RPMI medium with 0.1% BSA. Prepara-
tions of purified enterocytes were greater than 90%
viable, free of macrophages and B cell contamination as
determined by staining with anti-CD14 and anti-CD20
mAb’s (Coulter Corp., Hialeah, Florida, USA), and con-
taminated with only 2–4% intraepithelial lymphocytes
(CD3+ cells). Enterocytes were stained with anti-Hsp110
(1:100 dilution of rabbit polyclonal) or an equivalent
dilution of normal rabbit serum, followed by FITC-
labeled goat anti-rabbit secondary antibody. Stained
enterocytes were analyzed on an EPICS Profile III flow
cytometer (Beckman Coulter Inc., Fullerton, California,
USA), as described previously (21).
Results
Soluble lumenal components induce expression of CD1d on
IECs. Monolayers of epithelial cells form a selective bar-
rier between the lumen of the intestine and the under-
lying intestinal mucosa. As a consequence, IECs are
constantly exposed to the lumenal environment and its
contents (22). To assess whether such exposure could
result in alterations in epithelial CD1d expression, T84
cells were cultured for varying periods of time with sol-
uble LC prepared as described and diluted in media to
final protein concentrations of 3 µg/ml and 6 µg/ml.
Figure 1a depicts cell surface ELISA using the CD1d-
specific antibody 51.1.3. OD values at 405 nm reflect
the degree of HRP-bound secondary antibody associa-
tion with 51.1.3 and therefore represent the relative lev-
els of cell surface CD1d expression. Of note, since baso-
lateral access is limited with cells grown on plastic (19),
these assays likely reflect a predominant apical CD1d
signal. Exposure of T84 cells to LC on the apical surface
resulted in a time-dependent increase in the level of cell
surface CD1d expression, peaking by 48 hours of expo-
sure. The degree of surface CD1d upregulation was also
dependent on the concentration of LC material pres-
ent in cultures, being significantly higher when cells
were exposed to 6 µg/ml (OD = 0.45 ± 0.029) rather
than 3 µg/ml (OD = 0.27 ± 0.032), compared with T84
cells incubated alone without exposure to LC material 
(OD = 0.05 ± 0.015, n = 6 at 48 hours, P < 0.01 by
ANOVA in comparison to 3 µg/ml/LC and 6 µg/ml
samples). The upregulation of CD1d by lumenal mate-
rial was observed with all LC samples analyzed, includ-
ing those from subjects with inflammatory bowel dis-
ease (data not shown). As a control for the induction of
CD1d expression, cells were cultured in the presence of
IFN-γ for 48 hours at a concentration of 1,000 IU/ml.
As in previous studies (10), IFN-γ elevated levels of
CD1d on the surface of T84 cells (OD = 0.32 ± 0.042, 
P < 0.01 compared with no IFN-γ). To determine whether
the effects of LC components on epithelial cell pheno-
type were specific to CD1d, levels of cell surface MHC
class II and ICAM-1 were also assessed by ELISA (Fig-
ure 1b). Upon exposure to IFN-γ at 1,000 U/ml for 48
hours, T84 cells displayed elevated levels of both MHC
class II and ICAM-1 expression. In contrast, however,
no significant alterations in the surface expression lev-
els of these two markers were detected in cultures treat-
ed with 6 µg/ml LC material over the same time period.
These results demonstrate that upregulation of CD1d
by LC is relatively specific.
To determine whether the LC response might be
polarized, we subjected T84 cells to LC exposure on the
apical or basolateral surface and assessed CD1d expres-
sion by ELISA. To do this, T84 cells were grown to elec-
trical confluence (transepithelial resistance >1,000
ohms × cm2) on permeable supports, and ELISA was
performed as described previously (19). Interestingly,
some degree of polarity was apparent. While apical
exposure to LC resulted in a greater than fourfold
induction of CD1d (OD = 0.37 ± 0.011 with LC com-
pared with OD = 0.08 ± 0.01 without LC, n = 5 at 48
hours, P < 0.01 by ANOVA), a less than twofold change
was observed when LC was delivered to the basolateral
surface (OD = 0.15 ± 0.005 with LC compared with 
OD = 0.08 ± 0.01 without LC, n = 5 at 48 hours, P < 0.05
by ANOVA). Such findings suggest that a degree of
polarity may exist in the LC response.
ELISA data shown in Figure 1 revealed the increased
levels of cell surface CD1d expression following expo-
sure of IECs to LC. To determine whether elevations in
surface CD1d levels were accompanied by an overall
increase in CD1d transcription, CD1d mRNA levels
Figure 1
Soluble components present within human LC selectively enhance
CD1d expression on the surface of IECs. (a) Cell surface ELISA of T84
monolayers following incubation with either 6 µg/ml (black bars) or
3 µg/ml (gray bars) of LC sample for varying periods of time. (b) Rel-
ative levels of CD1d, MHC class II, and ICAM-1 expression were com-
pared by ELISA on T84 cells incubated alone (CNT) or in the pres-
ence of 6 µg/ml LC sample (LC) for a period of 48 hours. As a
positive control for the detection of all inducible epithelial markers,
monolayers were exposed to IFN-γ for 48 hours at a final concentra-
tion of 1,000 IU/ml. ODs at 405 nm ± SEM, generated by ELISA,
were blanked against isotype-matched control antibodies.
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were analyzed by RT-PCR. As shown in Figure 2a, expo-
sure of T84 cells to 6 µg/ml LC resulted in an increase
in the level of mRNA encoded by the CD1d gene.
Increased mRNA levels were detectable by 4 hours of
cell culture and reached maximal levels by 12 hours.
Equal loading of total cell RNA was confirmed by par-
allel examination of the housekeeping gene GAPDH.
Detection of CD1d at the protein level was then
assessed by immunoprecipitation of CD1d from whole-
cell lysates using the antibodies D5 and 51.1.3. Contents
of immunoprecipitates were resolved by SDS-PAGE and
transferred to nitrocellulose, and CD1d was detected by
probing of membranes with the D5 antibody. The
results of immunoprecipitation using D5 are shown in
the left panel of Figure 2b. T84 cells, which had been
stably transfected with the cDNA-encoding CD1d
(T84d), have been previously characterized and are
known to express significantly higher levels of CD1d
than untransfected cells (8). Extracts from T84d cells
were used as a positive control. Blots of the proteins
immunoprecipitated from T84d cells with the D5 anti-
body revealed two major bands. The 37-kDa (open
arrowhead) and 48-kDa (filled arrowhead) bands have
been previously characterized and have been shown to
correlate with nonglycosylated and glycosylated forms,
respectively (9, 11, 23). After immunoblotting with the
D5 antibody, immunoprecipitated extracts of T84 cells
cultured in media alone revealed low levels of these two
CD1d protein bands. Incubation of cells with LC for 48
hours resulted in the detection of
increasing amounts of the 37- and 48-
kDa forms of CD1d as defined by D5
immunoprecipitation and Western blot-
ting. By 48–72 hours of culture with sol-
uble LC, the levels of CD1d protein
detected were similar to that detected in
the T84d samples. Immunoprecip-
itation with 51.1.3, which primarily rec-
ognizes mature, fully glycosylated CD1d
(11), also revealed an increase in the level
of the 48-kDa form of CD1d (Figure 2b,
right panel, filled arrowhead).
Characterization of CD1d protein
expression was also assessed, using
confocal microscopy (Figure 2c). T84
cells grown to confluence and cultivat-
ed under varying conditions were per-
meabilized and stained with a combi-
nation of the 51.1.3 antibody and an
antibody specific for the tight-junction
protein ZO-1. Incubation of cells with
isotype-matched antibody controls
resulted in no specific staining (data
not shown). Under all conditions, cell
outlines were distinguished by ZO-1
border staining. Cells cultivated in the
presence of media alone displayed a
low degree of CD1d staining (Figure
2c, left panel), while culture of cells
with IFN-γ (1,000 U/ml) for 48 hours resulted in
increased levels of CD1d observed throughout cell
cross sections (Figure 2c, right panel). CD1d-specific
staining of IFN-γ–treated samples appeared granular
and diffuse throughout the monolayer. Similarly, expo-
sure of T84 cells to LC material for 48 hours resulted in
a significant increase in the degree of CD1d-specific
staining above that observed in control monolayers.
Taken together, the results illustrated in Figures 1 and
2 demonstrate the ability of soluble components pres-
ent within LC to upregulate CD1d protein and mRNA
expression. Elevated levels of CD1d by LC are compa-
rable to the levels observed in cells treated with IFN-γ
or transfected with a construct containing the CD1d
gene and controlled with an exogenous promoter (8).
LC-induced CD1d is not limited to T84 cells. To establish
that the effects of LC on CD1d expression were not spe-
cific to the T84 cell line, levels of CD1d were examined
on other epithelium-derived lines, namely HT-29 and
Caco-2, following exposure to LC material. As shown
by ELISA in Figure 3a, culture of HT-29 cells with LC
material at a concentration of 6 µg/ml resulted in a
time-dependent increase in cell surface CD1d expres-
sion. As with T84 cells, CD1d expression reached max-
imal levels by 48 hours of culture and was quantita-
tively comparable to the levels observed in samples
treated with 1,000 U/ml IFN-γ.
In subsets of experiments, we also examined whether
LC induced CD1d on cell types other than epithelia.
Figure 2
LC-induced upregulation of cell surface CD1d expression is accompanied by an ele-
vation in the levels of CD1d-encoded mRNA transcripts and protein. (a) RT-PCR of
total RNA isolated from T84 cells treated for varying lengths of time with media con-
taining 6 µg/ml human LC sample. Primers specific to CD1d and the housekeeping
gene GAPDH were used as described. (b) Immunoprecipitation (IP) of whole-cell
lysates following treatment with LC material, using the CD1d-specific antibodies D5
and 51.1.3. Immunoprecipitates were resolved by 12% SDS-PAGE under nonreducing
conditions. Proteins were transferred to nitrocellulose, and CD1d was detected by
immunoblotting with the D5 antibody. Locations of 48-kDa (filled arrowhead) and
37-kDa (open arrowhead) forms of CD1d are indicated. The molecular weight is indi-
cated on the left. (c) Confocal microscopy of T84 cells following incubation for 48
hours alone or in the presence of LC sample (6 µg/ml) or IFN-γ (1,000 IU/ml). CD1d
(green) and the tight-junction marker ZO-1 (red) were stained with FITC- and Texas
red–conjugated antibodies, respectively.
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Specifically, we addressed whether microvascular
endothelial CD1d might be regulated by LC. Such
experiments revealed that while IFN-γ (300 U/ml, 48
hours) increased CD1d on the surface of microvascu-
lar endothelia (2.5 ± 0.6–fold increase in OD by ELISA,
P < 0.01 compared with no IFN-γ), LC did not influence
endothelial CD1d (0.3 ± 0.2–fold increase in OD by
ELISA, P = not significant compared with no IFN-γ).
Cell surface ELISA of Caco-2 cells was not performed,
since adherence of epithelial monolayers proved insuf-
ficient to withstand extensive washing necessary for the
procedure (data not shown). Therefore, whole-cell
CD1d levels were next examined for both HT-29 and
Caco-2 cultures by probing of lysates resolved by West-
ern blot. Immunoblots of extracts obtained from 
HT-29 cells cultivated in media alone revealed the pres-
ence of two bands of approximately 46–48 kDa when
probed with the D5 antibody. Following exposure of
HT-29 cells to LC material for 24–48 hours, a band of
37 kDa and increased intensity of the 46- to 48-kDa
bands were detected in the cell extracts. Of note, and as
we have previously reported (11), whereas the 51.1.3
antibody recognizes mature CD1d, the D5 mAb pref-
erentially recognizes immature CD1d that has not yet
acquired maturation of the carbohydrate side-chain
modifications. Therefore, it is likely that the middle
bands observed within the D5 Western blot represent
immature CD1d with partially processed carbohydrate
side-chain modifications. The migration pattern of
these inducible bands matched the patterns observed
in the immunoblots of T84d extracts (data not shown)
and presumably represents forms of CD1d that vary in
their degree of glycosylation. Immunoblots of lysates
obtained from Caco-2 cells also revealed the induction
of CD1d-specific bands following exposure to LC mate-
rial. As with the T84 and HT-29 cells, a band of 37 kDa
and bands between 46 and 48 kDa became readily visi-
ble after 48 hours of cultivation in the presence of sol-
uble LC. In both cases, β-actin Western blotting was
used to demonstrate equal loading (Figure 3b). Thus,
such LC-induced upregulation of CD1d expression was
not specific for T84 cells but may be rather specific for
intestinal epithelia.
Non–microbe-derived, heat-labile components isolated from
the lumen of the murine intestinal tract stimulate CD1d upreg-
ulation on the surface of T84 cells. To better define the origin
of CD1d-inducing activity in LC, soluble LC were isolat-
ed from the intestinal tract of mice and tested for their
influence on CD1d expression by T84 cell ELISA. Incu-
bation of T84 cells with 6 µg/ml lumenal extracts
obtained from mice housed under SPF conditions
resulted in the induction of CD1d cell surface expression
by 48 hours of culture (Figure 4a). To determine whether
the murine CD1d-inducing factor was derived from
components of the microbial flora, lumenal samples iso-
lated from mice bred under germfree conditions were
incubated with T84 cells. Exposure of T84 cells to
germfree lumenal extracts led to elevations in surface
CD1d levels that did not differ significantly from the lev-
els induced by SPF-derived lumenal samples. These data
demonstrate that lumenal extracts devoid of microbial
content are capable of upregulating CD1d expression on
Figure 3
Soluble LC material elevates CD1d expression in the colonic epitheli-
um-derived cell lines HT-29 and Caco-2. (a) CD1d-specific cell surface
ELISA of confluent monolayers of HT-29 cells following incubation
with LC samples. As a positive control, cells were exposed to IFN-γ at
a final concentration of 1,000 IU/ml for a period of 48 hours. (b)
Western blot of whole-cell lysates isolated from HT-29 and Caco-2
cells following treatment with soluble LC material at a concentration
of 6 µg/ml. Proteins contained within the lysates were resolved by 12%
SDS-PAGE and transferred to nitrocellulose. The presence of CD1d
was subsequently assessed by probing with the anti-human CD1d-spe-
cific antibody D5. CD1d was observed as dominant bands of 48-kDa
(filled arrowhead) and 37-kDa (open arrowhead) forms. No bands
were detected when nitrocellulose membranes were probed with nor-
mal mouse serum (data not shown). The blots were reprobed for the
presence of β-actin (bottom panels).
Figure 4
Non–microbe-derived factors are present within the lumen of the murine small and
large intestine that upregulate CD1d expression on human T84 cells. Cell surface
ELISA was performed on confluent T84 monolayers using the CD1d-specific antibody
51.1.3. (a) BALB/c mice housed in either germfree (GF) or SPF environments were
sacrificed and the LC of the colon isolated. T84 cells were cultured alone (–) or
exposed to the soluble lumenal preparations for 48 hours at a final concentration of
6 µg/ml. (b) Lumenal material from the stomach (St), small intestine (SI), or large
intestine (LI) of SPF-housed mice was tested for its ability to enhance epithelial cell
surface CD1d expression. The CD1d-inducing activity of both soluble lumenal com-
ponents (black bars) and mucosal scrapings (gray bars) was assessed relative to
untreated controls (–).
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epithelial cells, implicating a non–microbe-derived com-
ponent as the active CD1d-inducing factor.
It is also possible that LPS contributes to this CD1d-
inducing activity, even in germfree animals (e.g., LPS in
autoclaved food, water, etc.). Therefore, we examined
whether LPS might induce CD1d. T84 cells exposed to
LPS (derived from Salmonella minnesota; range 0.01–100
ng/ml in the presence of 5% normal human serum)
resulted in no change in CD1d expression compared
with controls (maximal increase 0.2 ± 0.1–fold, P = not
significant). As controls, monolayers treated in a similar
fashion and assessed for ICAM-1 induction resulted in a
rapid and concentration-dependent elevation in ICAM-1
surface expression (maximal increase 18 ± 0.8–fold, 
P < 0.01). Such findings demonstrate that, while epithe-
lia can respond to LPS, it is unlikely that CD1d-induc-
ing activity in LC represents LPS.
To establish the region of the gastrointestinal tract
displaying the highest degree of CD1d-inducing activ-
ity, lumenal samples and mucosal scrapings were iso-
lated from the small intestine, the large intestine, and
the stomach. Figure 4b reveals that induction of CD1d
expression on T84 cells was greatest when cells were
incubated with mucosal and lumenal extracts from the
small intestine. Upregulation of CD1d was clearly
detectable in cultures containing large bowel–derived
samples, but not across monolayers cultured in the
presence of stomach-derived material. These data
demonstrate that the active CD1d-inducing compo-
nent is present both along the mucous layer lining the
epithelium and in the lumen of the gut itself. Maxi-
mum activity is present within regions of the proximal
small intestine. In contrast, no activity could be detect-
ed in contents obtained from the stomach.
Identification of Hsp110 as the CD1d-inducing activity. To
begin to characterize the active component within LC
responsible for induction of CD1d expression, we ini-
tially examined heat stability, hydrophobicity, and
nominal molecular size of the active LC component(s).
To determine whether the activity was heat sensitive,
soluble LC components were incubated at 80°C for 10
minutes and then exposed to cell monolayers. In con-
trast to unmodified LC material, heat-treated samples
did not elicit a detectable elevation in CD1d expression
(Figure 5a). Hydrophobicity of the active LC compo-
nent was determined by chloroform extraction or by
C18 column chromatography. For both separation
techniques, the CD1d-inducing activity partitioned
into the aqueous phase (Figure 5b). Molecular weight
fractionation was performed using the upper aqueous
phase of chloroform extracts as starting material. This
fraction was passed through a series of consecutively
lower–molecular weight cut-off filters. Retentates and
filtrates from each filtration procedure were subse-
quently tested on T84 cell monolayers for their ability
to stimulate CD1d expression. As indicated in Figure
5c, the retentate generated from filtration using the
100-kDa filter possessed the vast majority of activity, as
reflected by the ability of this fraction to upregulate
CD1d expression to a level comparable to that for
whole untreated LC material. The 100-kDa filtrate and
the fractions generated by its filtration through
lower–molecular weight filters displayed very little
CD1d-inducing activity. Identical results were obtained
with murine LC fractions from both SPF and germfree
mice (data not shown).
Using partially purified extract (aqueous phase fol-
lowing chloroform extraction eluted from C18 chro-
matography with molecular weight >100 kDa), SDS-
PAGE analysis revealed three distinct bands of Mr 85,
110, and 125 kDa by Coomassie staining (Figure 5d).
No specific sequence was obtained from the 85- or 125-
kDa bands. Microsequence analysis of tryptic peptides
from the approximately 110-kDa protein revealed three
peptides (sequences IEVPLHSLMEQTHLK, ELNNV-
CEPVVNQPKPK, and KPVTDCVISVPSFFTDAER)
with direct sequence homology to Hsp110 (15). As
shown in Figure 6a, Western blot analysis of unfrac-
Figure 5
Preliminary biochemical characterization of the active CD1d-inducing
factor present within soluble LC material. ELISA was performed on T84
cells treated for a period of 48 hours with various preparations of LC
isolates. (a) Monolayers were cultured alone (CNT), in the presence of
unmodified whole LC samples (–), or with LC samples that had been
preincubated at 80°C for 10 minutes. (b) LC material was separated
into aqueous (AQ) or hydrophobic (HP) phase by chloroform extrac-
tion and C18 column chromatography, respectively, as indicated. Indi-
vidual fractions were subsequently assessed for their ability to induce
CD1d expression. (c) LC samples were passed through a Centricon fil-
ter (Millipore Corp., Bedford, Massachusetts, USA) of 100-kDa molec-
ular weight cut-off. The 100-kDa filtrate was then passed consecutively
through 30-kDa and 10-kDa Centricon filters. The filtrates (white bars)
and retentates (gray bars) from each filtration step were subsequent-
ly resuspended in PBS, tested for their CD1d-inducing activity (black
bars), and compared with those from the no-treatment (CNT) and
crude-fraction (LC) groups. (d) Coomassie-stained SDS-PAGE gel of
partially purified material, indicating the major bands selected for
microsequencing (arrows), and the migration position of the band
with sequence homology to Hsp110. A control (CNT) derived from
a100-kDa filtrate fraction is also shown.
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tionated human LC material revealed the presence of an
antigen consistent with purified Hsp110, with slightly
slower mobility by SDS-PAGE, likely related to an as-yet
undetermined posttranscriptional and/or posttransla-
tional modification. Similar analysis with primary anti-
body omitted revealed no detectable signal. Taken
together, these studies suggest the presence of relative-
ly high concentrations of Hsp110 in our LC fractions.
As proof of principle for Hsp110-mediated induc-
tion of CD1d, two antibody-antigen approaches were
used. First, as shown in Figure 6b, the addition of
increasing concentrations of anti-Hsp110, but not
control anti-Hsp30, to LC extracts resulted in
decreased CD1d-inducing activity in a concentration-
dependent fashion (P < 0.025 by ANOVA). Second, as
shown in Figure 6c, the addition of purified mam-
malian Hsp110 to epithelial monolayers resulted in a
concentration-dependent induction of CD1d by sur-
face ELISA (P < 0.025 by ANOVA). The addition of
anti-Hsp110, but not anti-Hsp30, significantly dimin-
ished CD1d-inducing activity of purified Hsp110 pro-
tein (P < 0.05). Taken together, these data identify
Hsp110 as a component of the LC extract, presumably
derived from the IEC itself, in the autocrine regulation
of epithelial CD1d cell surface expression.
Finally, given the nonmicrobial origin of Hsp110 (Fig-
ure 4a) consistent with the absence of known prokary-
otic Hsp110 isoforms (15), and the relative abundance
of CD1d-inducing activity in the small intestine (Figure
4b), we questioned the origin of Hsp110 within LC.
First, we addressed whether Hsp110 was detectable on
native enterocytes. As shown in Figure 6d, flow cyto-
metric analysis of native small intestine enterocytes
revealed dominant Hsp110 surface expression. Inter-
estingly, exposure of native epithelia to recombinant
Hsp110 (10 µg/ml, 24 hours) did not induce CD1d
expression above base line (data not shown), suggesting
that in the native state, this signaling pathway may
already be saturated. To morphologically confirm these
findings, immunohistochemistry was performed on
normal small intestine (n = 3) and large intestine (n = 2)
tissue samples (Figures 6, e and f, respectively). These
studies revealed abundant expression of Hsp110 in
small intestinal samples, with prominent localization to
the epithelium and patchy staining within the lamina
propria. Hsp110 expression within large intestinal
epithelia was also evident, although less prominent
than in the small intestine (Figure 6f). Taken together,
these findings indicate that the epithelium is a rich
source of Hsp110 in the intestine and, as such, likely
reflects the CD1d-inducing activity evident in LC.
Discussion
The ability of CD1d to stimulate immune responses
that regulate intestinal inflammation implicates this
molecule as an important component of the mucosal
immune system (8). Characterization of the events that
regulate CD1d expression in general, and on the sur-
face of IECs in particular, promises to reveal further
information as to the functional role of CD1d. Similar
to other MHC class I–related molecules, CD1d expres-
sion and function are regulated by IFN-γ (10). Howev-
er, little is known about other endogenous pathways
for such regulation. We demonstrate here that lumenal,
IEC-derived Hsp110 represents a novel regulatory com-
ponent for CD1d expression on epithelia.
A number of previous studies have suggested discor-
dant in vivo and in vitro expression of CD1d; namely,
that CD1d expression is higher in vivo than in in vitro
Figure 6
Role of Hsp110 in induction of epithelial CD1d. (a) Western blot
analysis of LC for Hsp110. LC or purified recombinant Hsp110 (0.3
µg) was resolved by SDS-PAGE under nonreducing conditions, and
blots were probed with polyclonal rabbit anti-Hsp110. Also shown
is the control with primary antibody omitted from the reaction mix-
ture. A nonspecific band (NS) of approximately 70 kDa was observed
in both LC and control samples. (b) Cell surface ELISA of T84 mono-
layers following incubation with 6 µg/ml LC in the presence of indi-
cated concentrations of anti-Hsp110 or control anti-Hsp30. (c) Cell
surface ELISA of T84 monolayers following incubation with indicat-
ed concentrations of purified recombinant Hsp110 in the presence
of anti-Hsp110 or control anti-Hsp30. OD values generated by ELISA
were blanked against isotype-matched control antibodies. (d) Flow
cytometric analysis of Hsp110 on native small intestinal enterocytes
(black line) compared with equivalent concentrations of an isotype-
matched control (gray line). (e and f) Immunohistochemical local-
ization of Hsp110 in normal small intestinal tissue (e) and in normal
colon (f). Positive staining with anti-Hsp110 but not with control Ig
(Control) is seen in epithelial cells and diffusely in the lamina pro-
pria. Magnification, ×400.
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culture systems. Such studies suggest the possibility
that additional endogenous components may be neces-
sary to induce and/or maintain surface levels of epithe-
lial CD1d. As such, we screened human and murine LC
for the existence of CD1d-inducing bioactivity. Such
experiments revealed a prominent factor(s) that parti-
tions into high–molecular weight, aqueous-phase com-
ponents. A possibility was that LPS may represent the
CD1d-inducing activity. However, four observations
ruled out LPS. First, we directly demonstrated that LPS
does not regulate CD1d expression on T84 epithelium.
Second, LPS has been shown to induce ICAM-1 on IECs
(24), and our results indicated that LC fail to regulate
the expression of epithelial ICAM-1. Third, LC derived
from both conventionally housed mice and germfree
mice readily induced CD1d on human epithelia, likely
indicating that this activity is not LPS but is of eukary-
otic origin. Finally, the sensitivity of CD1d-inducing
activity to heat denaturation argued against LPS activi-
ty, since LPS is heat stable. Using biochemical and bio-
physical properties of this bioactivity, we identified
Hsp110 as an LC-derived agonist for CD1d expression.
Subsequent studies revealed that epithelia from the nor-
mal human intestine prominently express Hsp110, and
that purified Hsp110 can recapitulate the activity
observed in crude LC, suggesting an autocrine pathway
for Hsp110 function.
The mechanism(s) of CD1d induction by Hsp110 is
not known. It is possible that Hsp110 binds directly to
epithelial surface receptors and couples to intracellular
signaling. While much attention has been paid to
understanding the role of extracellular Hsp signaling
in a variety of disease states (25), mechanisms or sur-
face targets for Hsp’s are only recently appreciated. Of
distinct interest, several studies suggest that Toll-like
receptors (TLRs) may represent one class of receptors
for Hsp family members (26, 27) and that Hsp70 can
function as a “cytokine-like” molecule in association
with CD14 (28). We do not know whether Hsp110
binds to TLR-2 or TLR-4 or whether CD14 is necessary
for CD1d-inducing activity. IEC lines are known to
express functional TLRs (29, 30) and have been demon-
strated to signal in a CD14-dependent manner (31).
Similarly, since it was recently shown that CD40 is a
receptor for the Hsp70 family (32), it is possible that
CD40 provides a receptor for Hsp110. However, stud-
ies directed at this issue have revealed no detectable
CD40 on intestinal epithelia (L. Mayer, unpublished
observations). Another candidate molecule is CD91
(also called α2-macroglobulin receptor or the LDL-
related protein), as it has been demonstrated to bind
directly to a number of Hsp’s (33, 34). However, CD91
has not been shown to directly bind Hsp110, and little
is known about CD91 expression on intestinal epithe-
lia. Alternatively, it is possible that Hsp110 does not
bind directly to an epithelial surface receptor. Thus it
is possible that functional Hsp110 is in complex with
an as-yet unidentified peptide(s) that activates CD1d
via chaperone function and/or costimulation of other
surface molecules. All Hsp’s described to date have
attributable chaperone function (25), raising the dis-
tinct possibility that such chaperone function provides
an accessory signal for induction of CD1d.
At present, it is not known whether Hsp110-mediat-
ed regulation of CD1d represents a physiologic regula-
tory pathway or a process induced by immune activa-
tion. Given the constitutive presence of Hsp110 in the
lumen of all individuals examined, it might be argued
that Hsp110-mediated regulation of CD1d is a physio-
logic process. In the context of gut-associated lym-
phoid tissue, it could similarly be argued that Hsp110
regulation of CD1d represents the “physiologic inflam-
mation” associated with a number of mucosal tissue
sites (35). Some evidence exists that similar pathways
may be associated with pathological processes. It was
recently shown, for example, that increased expression
of Hsp family members (especially Hsp70) in athero-
sclerotic lesions coincides with specific expression of
CD1d, but not other MHC molecules (36). Whether
such observations can be extended to other Hsp mole-
cules is not known, but they suggest a relatively specif-
ic activation pathway for CD1d that involves Hsp-relat-
ed molecules. Our studies also shed some light on this
subject. Indeed, while IFN-γ regulates both MHC class
II and ICAM-1 on IECs (18), LC failed to modulate
either of these molecules. Thus, additional work will be
necessary to define the details of Hsp110-induced
CD1d expression.
In summary, these studies identify a novel function
elicited by LC of the intestinal milieu. Specifically,
results from these studies suggest that epithelia may
liberate Hsp110 and thus provide an autocrine signal
for CD1d regulation on this cell type. These studies
also predict a major role for Hsp110 in CD1d expres-
sion in other cells and provide evidence for yet another
link between innate and adaptive immunity in the
immunobiology of CD1d.
Acknowledgments
This work was supported by NIH grants DK-50189,
DK-44319, DK-51362, and DK-53056 and the Harvard
Digestive Diseases Center. R.S. Blumberg, L.F. Mayer,
and R.B. Sartor were supported by a grant from the
Broad Medical Research Program.
1. Blumberg, R.S., Gerdes, D., Chott, A., Porcelli, S.A., and Balk, S.P. 1995.
Structure and function of the CD1 family of MHC-like cell surface pro-
teins. Immunol. Rev. 147:5–29.
2. Briken, V., Moody, D.B., and Porcelli, S.A. 2000. Diversification of CD1
proteins: sampling the lipid content of different cellular compartments.
Semin. Immunol. 12:517–525.
3. Exley, M., et al. 2000. CD1d structure and regulation on human thymo-
cytes, peripheral blood T cells, B cells and monocytes. Immunology.
100:37–47.
4. Canchis, P.W., et al. 1993. Tissue distribution of the non-polymorphic
major histocompatibility complex class I-like molecule, CD1d. Immunol-
ogy. 80:561–565.
5. Blumberg, R.S., et al. 1991. Expression of a nonpolymorphic MHC class
I-like molecule, CD1d, by a human intestinal epithelial cells. J. Immunol.
147:2518–2524.
6. Saubermann, L.J., et al. 2000. Activation of natural killer T cells by alpha-
galactosylceramide in the presence of CD1d provides protection against
colitis in mice. Gastroenterology. 119:119–128.
754 The Journal of Clinical Investigation | September 2003 | Volume 112 | Number 5
7. Heller, F., Fuss, I.J., Nieuwenhuis, E.E., Blumberg, R.S., and Strober, W.
2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative coli-
tis, is mediated by IL-13-producing NK-T cells. Immunity. 17:629–638.
8. Colgan, S.P., Hershberg, R.M., Furuta, G.T., and Blumberg, R.S. 1999.
Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical
role of the cytoplasmic tail in autocrine signaling. Proc. Natl. Acad. Sci.
U. S. A. 96:13938–13943.
9. Somnay-Wadgaonkar, K., et al. 1999. Immunolocalization of CD1d in
human intestinal epithelial cells and identification of a beta2-
microglobulin-associated form. Int. Immunol. 11:383–392.
10. Colgan, S.P., Morales, V.M., Madara, J.L., Balk, S.P., and Blumberg, R.S.
1996. IFN-γ modulates CD1d expression on intestinal epithelia. Am. J.
Physiol. 271:C276–C283.
11. Kim, H.S., et al. 1999. Biochemical characterization of CD1d expression
in the absence of beta2- microglobulin. J. Biol. Chem. 274:9289–9295.
12. Exley, M., Porcelli, S., Furman, M., Garcia, J., and Balk, S. 1998. CD161
(NKR-P1A) costimulation of CD1d-dependent activation of human T
cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha
chains. J. Exp. Med. 188:867–876.
13. Wang, X.Y., et al. 2000. Characterization of native interaction of hsp110
with hsp25 and hsc70. FEBS Lett. 465:98–102.
14. Collard, C.D., et al. 2002. Neutrophil-derived glutamate regulates vas-
cular endothelial barrier function. J. Biol. Chem. 2002:14801–14811.
15. Lee-Yoon, D., Easton, D., Murawski, M., Burd, R., and Subjeck, J.R.
1995. Identification of a major subfamily of large hsp70-like proteins
through the cloning of the mammalian 110-kDa heat shock protein. 
J. Biol. Chem. 270:15725–15733.
16. Parkos, C.A., et al. 1996. CD 47 mediates post-adhesive events required
for neutrophil migration across polarized intestinal epithelia. J. Cell Biol.
132:437–450.
17. Schultz, M., et al. 1999. IL-2-deficient mice raised under germfree con-
ditions develop delayed mild focal intestinal inflammation. Am. J. Phys-
iol. 276:G1461–G1472.
18. Colgan, S.P., et al. 1994. Interferon-γ induces a surface phenotype
switch in intestinal epithelia: downregulation of ion transport and
upregulation of immune accessory ligands. Am. J. Physiol.
267:C402–C410.
19. Parkos, C.A., et al. 1996. Expression and polarization of intercellular
adhesion molecule-1 on human intestinal epithelia: consequences for
CD11b/18-mediated interactions with neutrophils. Mol. Med.
2:489–505.
20. Mizoguchi, E., Mizoguchi, A., and Bhan, A.K. 1997. Role of cytokines in
the early stages of chronic colitis in TCR alpha-mutant mice. Lab. Invest.
76:385–397.
21. Panja, A., Blumberg, R.S., Balk, S.P., and Mayer, L. 1993. CD1d is
involved in T cell-intestinal epithelial cell interactions. J. Exp. Med.
178:1115–1119.
22. Pitman, R.S., and Blumberg, R.S. 2000. First line of defense: the role of
the intestinal epithelium as an active component of the mucosal
immune system. J. Gastroenterol. 35:805–814.
23. Balk, S.P., et al. 1994. β2-Microglobulin-independent MHC class Ib mol-
ecule expressed by human intestinal epithelium. Science. 265:259–262.
24. Canny, G., et al. 2002. Lipid mediator-induced expression of bacterici-
dal/permeability-increasing protein (BPI) in human mucosal epithelia.
Proc. Natl. Acad. Sci. U. S. A. 99:3902–3907.
25. Li, Z., Menoret, A., and Srivastava, P. 2002. Roles of heat-shock proteins
in antigen presentation and cross-presentation. Curr. Opin. Immunol.
14:45–51.
26. Ohashi, K., Burkart, V., Flohe, S., and Kolb, H. 2000. Cutting edge: heat
shock protein 60 is a putative endogenous ligand of the toll-like recep-
tor-4 complex. J. Immunol. 164:558–561.
27. Asea, A., et al. 2002. Novel signal transduction pathway utilized by
extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J. Biol.
Chem. 277:15028–15034.
28. Asea, A., et al. 2000. HSP70 stimulates cytokine production through a
CD14-dependent pathway, demonstrating its dual role as a chaperone
and cytokine. Nat. Med. 6:435–442.
29. Cario, E., et al. 2000. Lipopolysaccharide activates distinct signaling
pathways in intestinal epithelial cell lines expressing Toll-like receptors.
J. Immunol. 164:966–972.
30. Gewirtz, A.T., Navas, T.A., Lyons, S., Godowski, P.J., and Madara, J.L.
2001. Cutting edge: bacterial flagellin activates basolaterally expressed
tlr5 to induce epithelial proinflammatory gene expression. J. Immunol.
167:1882–1885.
31. Pugin, J., et al. 1993. Lipolysaccharide activation of human endothelial
and epithelial cells is mediated by lipopolysacchride-binding protein
and soluble CD14. Proc. Natl. Acad. Sci. U. S. A. 90:2744–2748.
32. Becker, T., Hartl, F.U., and Wieland, F. 2002. CD40, an extracellular
receptor for binding and uptake of Hsp70-peptide complexes. J. Cell Biol.
158:1277–1285.
33. Binder, R.J., Han, D.K., and Srivastava, P.K. 2000. CD91: a receptor for
heat shock protein gp96. Nat. Immunol. 1:151–155.
34. Basu, S., Binder, R.J., Ramalingam, T., and Srivastava, P.K. 2001. CD91
is a common receptor for heat shock proteins gp96, hsp90, hsp70, and
calreticulin. Immunity. 14:303–313.
35. Nagler-Anderson, C. 2001. Man the barrier! Strategic defences in the
intestinal mucosa. Nat. Rev. Immunol. 1:59–67.
36. Bobryshev, Y.V., and Lord, R.S. 2002. Expression of heat shock protein-
70 by dendritic cells in the arterial intima and its potential significance
in atherogenesis. J. Vasc. Surg. 35:368–375.
